JP5302328B2 - 造血性新生物を治療するための方法 - Google Patents

造血性新生物を治療するための方法 Download PDF

Info

Publication number
JP5302328B2
JP5302328B2 JP2010535108A JP2010535108A JP5302328B2 JP 5302328 B2 JP5302328 B2 JP 5302328B2 JP 2010535108 A JP2010535108 A JP 2010535108A JP 2010535108 A JP2010535108 A JP 2010535108A JP 5302328 B2 JP5302328 B2 JP 5302328B2
Authority
JP
Japan
Prior art keywords
composition
combretastatin
cells
cell
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010535108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504510A5 (https=
JP2011504510A (ja
Inventor
デイビッド チャプリン，
ブロンウィン ジー． シーム，
Original Assignee
オキシジーン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オキシジーン， インコーポレイテッド filed Critical オキシジーン， インコーポレイテッド
Publication of JP2011504510A publication Critical patent/JP2011504510A/ja
Publication of JP2011504510A5 publication Critical patent/JP2011504510A5/ja
Application granted granted Critical
Publication of JP5302328B2 publication Critical patent/JP5302328B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2010535108A 2007-11-21 2008-11-21 造血性新生物を治療するための方法 Expired - Fee Related JP5302328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
US60/989,786 2007-11-21
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (3)

Publication Number Publication Date
JP2011504510A JP2011504510A (ja) 2011-02-10
JP2011504510A5 JP2011504510A5 (https=) 2012-12-27
JP5302328B2 true JP5302328B2 (ja) 2013-10-02

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535108A Expired - Fee Related JP5302328B2 (ja) 2007-11-21 2008-11-21 造血性新生物を治療するための方法

Country Status (12)

Country Link
US (4) US20090192098A1 (https=)
EP (1) EP2219451B1 (https=)
JP (1) JP5302328B2 (https=)
AU (1) AU2008326251B2 (https=)
CA (1) CA2703283C (https=)
DK (1) DK2219451T3 (https=)
ES (1) ES2529434T3 (https=)
HR (1) HRP20150040T1 (https=)
PL (1) PL2219451T3 (https=)
PT (1) PT2219451E (https=)
SI (1) SI2219451T1 (https=)
WO (1) WO2009067706A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075016A1 (en) * 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2012088438A1 (en) * 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
EP3337495A4 (en) * 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US11478445B2 (en) * 2017-10-25 2022-10-25 Bionomics Ltd. Method for treating acute myeloid leukemia
WO2020150326A1 (en) * 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ZA982523B (en) 1997-03-26 1999-10-04 Biosource Tech Inc Di-aryl ethers and their derivatives as anti-cancer agents.
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999034788A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
AU3109199A (en) 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
ES2267255T3 (es) 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
AU2190700A (en) 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
WO2001068654A2 (en) * 2000-03-10 2001-09-20 Baylor University Tubulin binding ligands and corresponding prodrug constructs
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US6777578B2 (en) 2000-04-27 2004-08-17 Arizona Board Of Regents Hydroxyphenstatin and the prodrugs thereof
US7078552B2 (en) * 2000-04-27 2006-07-18 Arizona Board Of Regents Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs
DE60107234T2 (de) 2000-05-09 2005-10-27 Arizona Board of Regents, acting for and on behalf of Arizona State University, Tempe Antitubulinanordnung und zellenwachstumshemmstoff "dioxostatin"
BR0110877A (pt) * 2000-05-15 2003-03-11 Celgene Corp Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU2001296215A1 (en) * 2000-07-17 2002-01-30 Oxi-Gene, Inc. Efficient method of synthesizing combretastatin a-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
AU2002216228A1 (en) 2000-12-21 2002-07-01 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
CA2463902A1 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
JP2005514450A (ja) 2001-12-21 2005-05-19 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−２プロドラッグの合成
WO2003082271A2 (en) 2002-04-03 2003-10-09 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
CA2516078C (en) 2003-02-28 2014-04-29 Oxigene, Inc. Catechol compositions and use thereof
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
EP1896391B1 (en) 2005-06-14 2015-08-12 Baylor University Combretastatin analogs with tubulin binding activity
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms

Also Published As

Publication number Publication date
US20120270831A1 (en) 2012-10-25
US9040500B2 (en) 2015-05-26
EP2219451A4 (en) 2011-01-19
SI2219451T1 (sl) 2015-02-27
ES2529434T3 (es) 2015-02-20
US20150246064A1 (en) 2015-09-03
AU2008326251A1 (en) 2009-05-28
US20090192098A1 (en) 2009-07-30
WO2009067706A1 (en) 2009-05-28
DK2219451T3 (en) 2015-01-12
EP2219451B1 (en) 2014-11-12
US20090264382A1 (en) 2009-10-22
CA2703283C (en) 2016-01-12
PT2219451E (pt) 2015-02-09
PL2219451T3 (pl) 2015-04-30
EP2219451A1 (en) 2010-08-25
JP2011504510A (ja) 2011-02-10
AU2008326251B2 (en) 2014-03-06
CA2703283A1 (en) 2009-05-28
HRP20150040T1 (hr) 2015-02-27

Similar Documents

Publication Publication Date Title
JP5302328B2 (ja) 造血性新生物を治療するための方法
Chen et al. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
WO2020024976A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
EP3318276A1 (en) Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP2022081527A (ja) 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
KR20100137570A (ko) 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
EP3151864B1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
RU2492865C2 (ru) Комбинированное применение производных холестанола
US20250275938A1 (en) Compositions and methods for treatment of cancer
WO2018203127A1 (en) Compositions for treatment of malignant tumors and precancerous conditions, methods of use thereof and methods for manufacturing medicaments
Mostafa et al. Combined Effect of doxorubicin and pyrogallol on tongue squamous cell carcinoma SCC-25 Cells, an in vitro study
JP7186731B2 (ja) 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
Dorr et al. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines
CN118302169A (zh) 治疗癌症或血液疾病的方法
JP6581308B2 (ja) 癌治療剤
Atef et al. Synergistic anticancer effects of Dracaena cinnabari and Aloe perryi extracts on colorectal cancer cells: A flow cytometry analysis of toxicity, cell cycle, apoptosis, and autophagy
EP1658084A2 (en) Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
CA3209477A1 (en) Compositions and methods for treating cancer
US7985738B2 (en) Cytosine nucleoside analogs and isoflavones and uses thereof
JP2020075894A (ja) 抗血液悪性腫瘍薬
HK40025641A (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130620

R150 Certificate of patent or registration of utility model

Ref document number: 5302328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees